Upregulation of lncRNA LANCL1-AS1 inhibits the progression of non-small-cell lung cancer via the miR-3680-3p/GMFG axis

Hui, Pei; Peng, Jing; Xiao-ni, Qiao; Gao, Han

doi:10.1515/med-2023-0666

Cited by 4 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gan et al found that let-7d-5p expression was remarkably increased in LC cells treated with Trametes robiniophila, and its upregulation inhibited angiogenesis and tumor growth in LC by targeting NAP1L1 (134). Chang et al demonstrated that exosomal miR-197-3p from LUAD cells could facilitate the angiogenesis of HUVECs by directly downregulating TIMP2/3 (135). Furthermore, Pan et al discovered that LANCL1-AS1 upregulation dramatically repressed the angiogenesis of NSCLC cells by upregulating glia maturation factor gamma via sponging miR-3680-3p (136).…”

Section: Ncrna In Lc Angiogenesismentioning

confidence: 99%

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Liu,

Ding,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer (LC) is a heterogeneous disease with high malignant degree, rapid growth, and early metastasis. The clinical outcomes of LC patients are generally poor due to the insufficient elucidation of pathological mechanisms, low efficiency of detection and assessment methods, and lack of individualized therapeutic strategies. Non-coding RNAs (ncRNAs), including microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA), are endogenous regulators that are widely involved in the modulation of almost all aspects of life activities, from organogenesis and aging to immunity and cancer. They commonly play vital roles in various biological processes by regulating gene expression via their interactions with DNA, RNA, or protein. An increasing amount of studies have demonstrated that ncRNAs are closely correlated with the initiation and development of LC. Their dysregulation promotes the progression of LC via distinct mechanisms, such as influencing protein activity, activating oncogenic signaling pathways, or altering specific gene expression. Furthermore, some ncRNAs present certain clinical values as biomarker candidates and therapeutic targets for LC patients. A complete understanding of their mechanisms in LC progression may be highly beneficial to developing ncRNA-based therapeutics for LC patients. This review mainly focuses on the intricate mechanisms of miRNA, lncRNA, and circRNA involved in LC progression and discuss their underlying applications in LC treatment.

show abstract

Section: Ncrna In Lc Angiogenesismentioning

confidence: 99%

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Liu,

Ding,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

MiR‐3680‐3p is a novel biomarker for the diagnosis and prognosis of liver cancer and is involved in regulating the progression of liver cancer

Tang,

Li,

Zhou

et al. 2024

IUBMB Life

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non‐coding RNAs that can actively participate in post‐transcriptional regulation of genes. A number of studies have shown that miRNAs can serve as important regulators of cancer cell growth, differentiation, and apoptosis. They can also act as markers for the diagnosis and prognosis of certain cancers. To explore the potential prognosis‐related miRNAs in liver cancer patients, to provide theoretical basis for early diagnosis and prognosis of liver cancer, as well as to provide a new direction for the targeted therapy of liver cancer. The miRNA expression profiles of liver cancer patients in the the Cancer Genome Atlas database were comprehensively analyzed and various prognostic‐related miRNAs of liver cancer were screened out. The data was further subjected to survival analysis, prognostic analysis, gene ontology and kyoto encyclopedia of genes and genomes enrichment analysis, microenvironment analysis, and drug sensitivity analysis by R Language version 4.2.0. Finally, the screened miRNAs were further validated by different experiments. Thus, miNRAs involved in liver cancer diagnosis and prognosis were identified. MiRNA‐3680‐3p was found to be significantly different in 10 different cancers, including liver cancer, and was significantly associated with the microenvironment, survival, and prognosis of liver cancer patients. In addition, drug sensitivity analysis revealed that miRNA‐3680‐3p can provide a useful reference for drug selection in targeted therapy for liver cancer. MiRNA‐3680‐3p can serve as a biomarker for the diagnosis and prognosis of liver cancer patients and down‐regulation of miRNA‐3680‐3p could significantly inhibit both the proliferation and migration of liver cancer cells.

show abstract

A review of the complex interplay between chemoresistance and lncRNAs in lung cancer

Alnefaie

2024

J Transl Med

View full text Add to dashboard Cite

Lung Cancer (LC) is characterized by chemoresistance, which poses a significant clinical challenge and results in a poor prognosis for patients. Long non-coding RNAs (lncRNAs) have recently gained recognition as crucial mediators of chemoresistance in LC. Through the regulation of key cellular processes, these molecules play important roles in the progression of LC and response to therapy. The mechanisms by which lncRNAs affect chemoresistance include the modulation of gene expression, chromatin structure, microRNA interactions, and signaling pathways. Exosomes have emerged as key mediators of lncRNA-driven chemoresistance, facilitating the transfer of resistance-associated lncRNAs between cancer cells and contributing to tumor development. Consequently, exosomal lncRNAs may serve as biomarkers and therapeutic targets for the treatment of LC. Therapeutic strategies targeting lncRNAs offer novel approaches to circumvent chemoresistance. Different approaches, including RNA interference (RNAi) and antisense oligonucleotides (ASOs), are available to degrade lncRNAs or alter their function. ASO-based therapies are effective at reducing lncRNA expression levels, increasing chemotherapy sensitivity, and improving clinical outcomes. The use of these strategies can facilitate the development of targeted interventions designed to disrupt lncRNA-mediated mechanisms of chemoresistance. An important aspect of this review is the discussion of the complex relationship between lncRNAs and drug resistance in LC, particularly through exosomal pathways, and the development of innovative therapeutic strategies to enhance drug efficacy by targeting lncRNAs. The development of new pathways and interventions for treating LC holds promise in overcoming this resistance.

show abstract

Upregulation of lncRNA LANCL1-AS1 inhibits the progression of non-small-cell lung cancer via the miR-3680-3p/GMFG axis

Cited by 4 publications

References 22 publications

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

MiR‐3680‐3p is a novel biomarker for the diagnosis and prognosis of liver cancer and is involved in regulating the progression of liver cancer

A review of the complex interplay between chemoresistance and lncRNAs in lung cancer

Contact Info

Product

Resources

About